First Mass Polio Vaccine Inoculations Begin

Context

Polio had become one of the most feared diseases in the United States by the early 1950s, with recurring summer epidemics that left thousands of children paralyzed or dead each year. The 1952 outbreak alone recorded more than 57,000 cases and over 3,000 deaths, prompting widespread public anxiety and the closure of swimming pools and playgrounds in affected areas. The National Foundation for Infantile Paralysis, popularly known as the March of Dimes, channeled donations from millions of Americans into research aimed at developing a preventive vaccine.

A critical scientific advance occurred in 1949 when John Enders, Thomas Weller, and Frederick Robbins at Boston Children’s Hospital succeeded in growing poliovirus in laboratory cultures of human tissue, work that earned them the 1954 Nobel Prize in Physiology or Medicine. Building on this foundation, virologist Jonas Salk at the University of Pittsburgh created an inactivated-virus vaccine. By 1953 he had already tested the preparation on himself and his family, demonstrating its safety in small-scale human trials before moving toward larger studies.

What Happened

The first injections took place on February 23, 1954, at Arsenal Elementary School in Pittsburgh’s Lawrenceville neighborhood. Salk and members of his research team personally administered the vaccine to a group of schoolchildren whose parents had consented to participation. These initial doses marked the formal start of the field evaluation of the Salk vaccine.

The Pittsburgh inoculations served as the pilot phase for a rapidly expanding program. Within weeks the trial grew to include additional schools in Pennsylvania and then spread across the United States, Canada, and Finland. Ultimately more than one million children took part in the coordinated effort, which employed careful record-keeping and, in its main phase beginning later that spring, double-blind placebo controls to assess efficacy.

Participation was voluntary and required parental permission; many families viewed involvement as both a personal safeguard and a contribution to public health. The trial design reflected close collaboration between academic researchers, public-health officials, and the March of Dimes, which helped coordinate logistics and funding.

Aftermath

On April 12, 1955, the results of the massive trial were announced in a nationally broadcast event: the vaccine proved safe and approximately 80–90 percent effective against paralytic polio. Licensing followed immediately, and pharmaceutical companies began large-scale production. Within two years annual U.S. polio cases fell from roughly 58,000 to under 6,000.

A temporary setback occurred in 1955 when a batch of vaccine produced by Cutter Laboratories caused a small number of cases, prompting stricter manufacturing standards, yet the overall rollout continued and confidence in the vaccine remained high.

Legacy

The 1954 trials demonstrated that coordinated, large-scale clinical testing could rapidly validate a new vaccine and translate laboratory success into public-health impact. Polio incidence in the United States and other developed nations declined dramatically, and by the early 1960s the disease had ceased to be a major threat in those regions.

Salk’s inactivated vaccine, later supplemented by Albert Sabin’s oral live-attenuated version, established enduring models for vaccine development, equitable distribution, and international immunization campaigns. The March of Dimes–funded effort also illustrated the power of public philanthropy in driving medical research, a pattern that influenced subsequent global health initiatives.